Ryzodeg® Offers Improved glycaemic Control With Significantly Lower Rates of Hypoglycaemia Compared to biphasic insulin aspart 30 in Adults With Type 2 Diabetes[1]

Ryzodeg® Offers Improved glycaemicRyzodeg® Offers Improved glycaemic Control With Significantly Lower Rates of Hypoglycaemia Compared to biphasic insulin aspart 30 in Adults With Type 2 Diabetes[1] PR Newswire COPENHAGEN, Denmark, December 2, 2013 Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance ®period (defined as week 16 onwards) with Ryzodeg compared to [1]biphasic insulin aspart 30, both administered twice-daily . To view the Multimedia News Release, please click: http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control ®Ryzodeg is the first combination of two distinct insulin analogues, ®Tresiba (insulin degludec), the once-daily basal insulin with an ultra-long ®duration of action, and the well-established mealtime insulin NovoRapid (insulin aspart), in the ratio of 70% and 30%, in one pen for people with [2]-[4]type 2 diabetes . "Type 2 diabetes is a progressive disease and many patients who are uncontrolled with basal insulin need to add mealtime insulin to achieve or ®maintain their glycaemic targets over time.